GSA Capital Partners’s Ascendis Pharma A/S ASND Stock Holding History

GSA Capital Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$286K	Buy	+1,071	New	+$250K	0.02%	1331
2025 Q1	–	Sell	-1,717	Closed	-$236K	–	1637
2024 Q4	$236K	Buy	+1,717	New	+$226K	0.02%	1334
2024 Q2	–	Sell	-6,564	Closed	-$992K	–	1613
2024 Q1	$992K	Buy	+6,564	New	+$937K	0.08%	443
2022 Q1	–	Sell	-8,175	Closed	-$1.1M	–	1393
2021 Q4	$1.1M	Buy	+8,175	New	+$1.22M	0.14%	168
2020 Q4	–	Sell	-2,676	Closed	-$413K	–	1195
2020 Q3	$413K	Buy	+2,676	New	+$385K	0.07%	511
2020 Q1	–	Sell	-2,174	Closed	-$302K	–	1051
2019 Q4	$302K	Buy	+2,174	New	+$242K	0.04%	1018
2016 Q3	–	Sell	-13,100	Closed	-$174K	–	1756
2016 Q2	$174K	Sell	13,100 -5,600	-30%	-$86.3K	0.01%	1609
2016 Q1	$347K	Buy	+18,700	New	+$332K	0.02%	1229

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

GSA Capital Partners's ASND Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 1,071 shares worth $286K. The stake represents 0.02% of the portfolio and ranks #1331 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in ASND as recently as Q4 2024.

GSA Capital Partners first reported a position in ASND in Q1 2016 and has held it in 8 quarters since. The position peaked at $1.1M in Q4 2021. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

GSA Capital Partners held 1,071 shares of Ascendis Pharma A/S worth $286K as of Q2 2026.
Ascendis Pharma A/S was a new GSA Capital Partners position in Q2 2026.
Ascendis Pharma A/S made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1331 holding.
GSA Capital Partners first reported a position in Ascendis Pharma A/S in Q1 2016 and has held it in 8 quarters since.
GSA Capital Partners's Ascendis Pharma A/S position peaked at $1.1M in Q4 2021.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.